Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

NCT02430480 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

NIH

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Goserelin
DRUG: Enzalutamide
DEVICE: mpMRI

Sponsor

National Cancer Institute (NCI)